NL8006135A - MEDICINAL PRODUCT WITH ANXIETY AND ANXIETY EQUIVALENTS EFFECTIVE EFFECT AND METHOD FOR PREPARING SUCH A MEDICINE. - Google Patents
MEDICINAL PRODUCT WITH ANXIETY AND ANXIETY EQUIVALENTS EFFECTIVE EFFECT AND METHOD FOR PREPARING SUCH A MEDICINE. Download PDFInfo
- Publication number
- NL8006135A NL8006135A NL8006135A NL8006135A NL8006135A NL 8006135 A NL8006135 A NL 8006135A NL 8006135 A NL8006135 A NL 8006135A NL 8006135 A NL8006135 A NL 8006135A NL 8006135 A NL8006135 A NL 8006135A
- Authority
- NL
- Netherlands
- Prior art keywords
- anxiety
- patients
- medicament
- trait
- aminobutyric acid
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims description 42
- 238000000034 method Methods 0.000 title claims description 9
- 230000036506 anxiety Effects 0.000 title description 10
- 230000000694 effects Effects 0.000 title description 4
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 22
- 239000002249 anxiolytic agent Substances 0.000 claims description 13
- 230000000949 anxiolytic effect Effects 0.000 claims description 11
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 8
- 229940049706 benzodiazepine Drugs 0.000 claims description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 4
- 230000000049 anti-anxiety effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229960004535 oxazepam Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 description 5
- 206010044565 Tremor Diseases 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010066392 Fear of death Diseases 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000033042 Somatoform disorder cardiovascular Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000009157 neurocirculatory asthenia Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Description
N/29.989-Kp/vD. - 1 -N / 29,989-Kp / vD. - 1 -
Geneesmiddel met angst en angstequivalenten opheffende werking en werkwijze voor de bereiding van een dergelijk geneesmiddel.Medicament with anxiety and anxiety equivalent lifting effect and method for the preparation of such a medicament.
De uitvinding heeft betrekking op een geneesmiddel met angst en angstequivalenten opheffende werking, werkzaam bij patiënten van het "trait-anxiety" type, alsmede op een werkwijze voor de bereiding van een geneesmiddel met een 5 dergelijke werking.The invention relates to a medicament having an anxiety and anxiety equivalent anti-anxiety effect, effective in patients of the "trait-anxiety" type, and to a method of preparing a medicament having such an effect.
Miljoenen patiënten met een of andere vorm van angst-neurose doen jaarlijks beroep op hulpinstanties, zoals artsen, psychologen, etc. teneinde van een dergelijke angstneurose af te komen. Het aantal patiënten zal in deze zich snel ontwikkelt) lende wereld jaarlijks eerder toenemen dan afnemen.Millions of patients with some form of anxiety neurosis call on help agencies such as doctors, psychologists, etc. each year to get rid of such anxiety neurosis. The number of patients in this rapidly developing world will increase rather than decrease annually.
Een definitie voor angstneurose wordt gegeven door Woodruff, R.A-,Goodwin, D.W. and Guze, S.B. Anxiety neurosis in: Psychiatrie Diagnosis, Oxford University Press, London, 1974 en Wheeler, E.O., White, P.D., Reed, E.W. and Cohen, 15 M.E. Neurocirculatory Aesthenia (Anxiety Neurosis, Effort Syndrome, Neurasthenia). Jama, 142, (1950), 12, biz. 878-889.A definition for anxiety neurosis is provided by Woodruff, R.A-, Goodwin, D.W. and Guze, S.B. Anxiety neurosis in: Psychiatry Diagnosis, Oxford University Press, London, 1974 and Wheeler, E.O., White, P.D., Reed, E.W. and Cohen, 15 M.E. Neurocirculatory Aesthenia (Anxiety Neurosis, Effort Syndrome, Neurasthenia). Jama, 142, (1950), 12, biz. 878-889.
De symptomen van de angstneurose, zoals gedefinieerd door Woodruff en Wheeler zijn in afnemende significantie: hartkloppingen, snelle vermoeidheid, kortademigheid, zenuwach-20 tigheid, pijn op de borst, zuchtverschijnselen, duizeligheid, gevoel van flauwvallen, bevreesdheid, hoofdpijn, tintelingen, zwakheid, trillingen, slechte ademhalingstechniek, slapeloosheid, angst, beverigheid, snelle vermoeibaarheid, transpireren, angst voor de dood, flauwtes, tremoren, frequent urineren, 25 braken, diarree, slechte eetlust en globusgevoelens.The symptoms of anxiety neurosis, as defined by Woodruff and Wheeler, are of diminishing significance: palpitations, rapid fatigue, shortness of breath, nervousness, chest pain, sighing symptoms, dizziness, feeling faint, anxiety, headache, tingling, weakness, tremors, poor breathing technique, insomnia, anxiety, shakiness, rapid fatiguability, sweating, fear of death, fainting, tremors, frequent urination, vomiting, diarrhea, poor appetite, and globus sensations.
De patiënten met angstneurosen kunnen globaal worden onderverdeeld in twee groepen, waarvan de ene de groep in een reactieve angsttoestand (state-anxiety) verkeert en de andere met een karakterologische angstneurose (trait-anxiety).Patients with anxiety neuroses can be broadly divided into two groups, one of which is in a reactive anxiety state (state anxiety) and the other with a characterological anxiety neurosis (trait anxiety).
30 De eerste groep van "state-anxiety" patiënten maakt ca. 50% van de totale angstneurosen uit, terwijl dienovereenkomstig de groep van "trait-anxiety" patiënten ca. 50% van de totale angstneurosen uitmaakt.The first group of "state-anxiety" patients accounts for about 50% of the total anxiety neuroses, while accordingly the group of "trait-anxiety" patients accounts for about 50% of the total anxiety neuroses.
Uit onderzoekingen is gebleken, dat het "state-· 35 anxiety" type patiënten over het algemeen positief reageren op 8006135 v - 2 - de toediening van bekende anxiolytica bijv. benzodiazepinen en zodoende in meer of mindere mate met succes geholpen kunnen worden.Studies have shown that the "state-anxiety" type of patients generally respond positively to 8006135 v-2 - the administration of known anxiolytics, e.g., benzodiazepines, and thus may be more or less successfully helped.
Voorts is gebleken, dat bij bepaalde patiënten, be-5 horende tot de "trait-anxiety" groep, waarbij de angstneurose van genetische constitutionele aard bleek, door toediening van de bekende anxiolytica niet het gewenste resultaat werd bereikt. Daarentegen bleek deze groep patiënten met succes te kunnen worden geholpen door toediening van baclofeen. Deze 10 groep maakt ca. 10% van de totale angstneurosegevallen uit. (Zie in dit verband de Nederlandse octrooiaanvrage 7706429).Furthermore, it has been found that in certain patients belonging to the "trait-anxiety" group, where the anxiety neurosis was of a genetic constitutional nature, the desired result was not achieved by administration of the known anxiolytics. In contrast, this group of patients was found to be successfully helped by the administration of baclophene. This 10 group makes up about 10% of the total anxiety neurosis cases. (See in this connection Dutch patent application 7706429).
Een ernstig individueel en maatschappelijk probleem vormt de overige groep van de eerder genoemde "trait-anxiety" patiënten, die ca. 40% van de totale aan angstneurose lijdende 15 patiënten uitmaakt.A serious individual and social problem is the remaining group of the aforementioned "trait-anxiety" patients, who make up about 40% of the total 15 patients suffering from anxiety neurosis.
Deze groep bleek niet geholpen te kunnen worden door toediening van hetzij de bekende anxiolytica hetzij baclofeen.This group has not been found to be helped by administration of either the known anxiolytics or baclophene.
Een doel van de uitvinding is een geneesmiddel te verschaffen, dat met succes kan worden gebruikt voor de be-20 handeling van "trait-anxiety" patiënten.An object of the invention is to provide a medicament which can be successfully used for the treatment of "trait-anxiety" patients.
Een ander doel van de uitvinding is een werkwijze te verschaffen voor de bereiding van een dergelijk geneesmiddel.Another object of the invention is to provide a method for the preparation of such a medicament.
Nog een ander doel van de uitvinding is het behande-25len van "trait-anxiety" patiënten.Yet another object of the invention is to treat "trait-anxiety" patients.
De uitvinding verschaft thans een geneesmiddel, waarmee verrassenderwijze de aanzienlijk grote groep van ca. 40% aan "trait-anxiety" neurose lijdende patiënten met succes kan worden behandeld.The invention now provides a medicament with which, surprisingly, the considerably large group of about 40% of trait-anxiety neurosis sufferers can be successfully treated.
30 Het geneesmiddel volgens de uitvinding heeft het kenmerk, dat het geneesmiddel een combinatie is van β-(p-halo-geenfenyl)γ-aminoboterzuur en een anxiolyticum, welk geneesmiddel deze componenten naast de farmacologisch aanvaardbare en gebruikelijke excipientia in een effectieve hoeveelheid 35bevat.The medicament according to the invention is characterized in that the medicament is a combination of β- (p-halo-phenyl) γ-aminobutyric acid and an anxiolytic, which medicament contains these components in an effective amount in addition to the pharmacologically acceptable and usual excipients.
Het is verrassend dat er een dergelijke combinatie geschikt is voor de succesvolle behandeling van de grote groep van "trait-anxiety" patiënten.It is surprising that such a combination is suitable for the successful treatment of the large group of "trait-anxiety" patients.
Wanneer het als eerste component gebruikte γ-amino-40boterzuur $-(p-chloorfenyl)-γ-aminoboterzuur is dan stelt deze 8006135 er* - 3 - verbinding een bekende stof voor, te weten baclofeen.When the γ-amino-40-butyric acid used as the first component is $ - (p-chlorophenyl) -γ-aminobutyric acid, this 8006135 * - 3 compound represents a known substance, namely baclophene.
Van de anxiolytica zijn de benzodiazepinen wel de meest bekende.Benzodiazepines are the best known of the anxiolytics.
Voorbeelden van dergelijke benzodiazepinen zijn 5 oxazepam (Seresta), lorazepam (Temesta), clonazepam (Rivotril), nitrazepam (Mogadon), chloordiazepoxide (Librium) , diazepam (Valium, Stesolid) , medazepam (Nobrium) , bromazepam (Lexotani2), enz.Examples of such benzodiazepines are oxazepam (Seresta), lorazepam (Temesta), clonazepam (Rivotril), nitrazepam (Mogadon), chlordiazepoxide (Librium), diazepam (Valium, Stesolid), medazepam (Nobrium), bromazepam (Lexotani2).
Een gunstige werking gaat uit van een geneesmiddel 10 met als werkzame bestanddelen baclofeen en een benzodiazepine, terwijl een combinatie, waarbij de halfwaardetijd van de werkzame bestanddelen ongeveer even groot is de voorkeur verdient, aangezien in een dergelijk geval de beide werkzame bestanddelen een vergelijkbare werkingsduur hebben.A favorable action is based on a medicament with the active ingredients baclophene and a benzodiazepine, while a combination in which the half-life of the active ingredients is approximately the same is preferred, since in such a case the two active ingredients have a comparable duration of action. .
15 Een dergelijke combinatie is baclofeen en oxazepam.One such combination is baclophene and oxazepam.
Voorts heeft de uitvinding betrekking op een werkwijze voor de bereiding van de geneesmiddelen volgens de uitvinding, waartoe als werkzame bestanddelen een 3-(p-halogeen-fenyl)-γ-aminoboterzuur en een anxiolyticum in een voor ge-20 neeskundige doeleinden geschikte toedieningsvorm worden gebracht.The invention further relates to a process for the preparation of the medicaments according to the invention, for which the active ingredients are a 3- (p-halo-phenyl) -γ-aminobutyric acid and an anxiolytic in a dosage form suitable for medicinal purposes. brought.
Bovendien beschrijft de uitvinding een werkwijze voor de behandeling van patiënten met angstneurose of angst-neurose-equivalenten en psychosomtische verwikkelingen, in het 25 bijzonder van het "trait-anxiety" type, met het kenmerk, dat het geneesmiddel volgens de uitvinding in een effectieve hoeveelheid wordt toegediend.Moreover, the invention describes a method for the treatment of patients with anxiety neurosis or anxiety neurosis equivalents and psychosomtic complications, in particular of the "trait-anxiety" type, characterized in that the medicament according to the invention in an effective amount is administered.
Voor het verkrijgen van de gewenste resultaten dient het geneesmiddel te worden toegediend in een zodanige dosering, 30 dat per dag van β-(p-halogeenfenyl)-γ-aminoboterzuur 5-30 mg wordt gebruikt en van het anxiolyticum 10-60 mg.To obtain the desired results, the drug should be administered in a dosage such that β- (p-halophenyl) -γ-aminobutyric acid is used 5-30 mg per day and 10-60 mg anxiolytic is used per day.
Zeer goede resultaten worden verkregen, wanneer per dag van de eerste component 10-15 mg wordt gebruikt en van de tweede component 25-35 mg.Very good results are obtained when 10-15 mg of the first component is used per day and 25-35 mg of the second component.
35 De optimale dosis wordt individueel bepaald en is afhankelijk van o.a. de aard en van de leeftijd van de patient, alsmede van de ernst van de neurose.The optimal dose is determined individually and depends, inter alia, on the nature and age of the patient, as well as on the severity of the neurosis.
Bij voorkeur worden de onderhavige geneesmiddelen in de vorm van een tablet toegediend, voorzien van een breukgleuf 40 zodat de per tablet gebruikte dosering op eenvoudige wijze kan 8006135 - 4 - worden gehalveerd hetzij door de patient/ hetzij door de behandelende arts.Preferably, the present medicaments are administered in the form of a tablet, provided with a score slot 40, so that the dosage used per tablet can be easily halved either by the patient / by the treating physician.
Bekend is, dat een groot aantal patiënten lijdende aan angstneuroses van de bovenbeschreven soort, hun toevlucht 5 neemt tot overmatig gebruik van alcohol, en/of langdurig gebruik van te hoge dosering anxiolytica zoals benzodiazepine met hinderlijke bijwerking als gevolg.It is known that a large number of patients suffering from anxiety neuroses of the type described above resort to excessive consumption of alcohol, and / or prolonged use of too high a dose of anxiolytics such as benzodiazepine resulting in a troublesome side effect.
80061358006135
Claims (5)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8006135A NL8006135A (en) | 1980-11-10 | 1980-11-10 | MEDICINAL PRODUCT WITH ANXIETY AND ANXIETY EQUIVALENTS EFFECTIVE EFFECT AND METHOD FOR PREPARING SUCH A MEDICINE. |
| BE0/206439A BE890988A (en) | 1980-11-10 | 1981-11-04 | MEDICINAL PRODUCT WITH ANXIETY AND ANXIETY EQUIVALENTS EFFECTIVE AND METHOD FOR PREPARING SUCH A MEDICINAL PRODUCT |
| FR8120935A FR2493703B1 (en) | 1980-11-10 | 1981-11-09 | MEDICINE BASED ON A B- (P-HALOGENOPHENYL) -G-AMINOBUTYRIC ACID AND AN ANXIOLYTIC |
| SE8106621A SE8106621L (en) | 1980-11-10 | 1981-11-09 | ACTIVITIES WITH ACTIVITY AGAINST OROSNEUROS AND SIMILAR NEUROS AND PROCEDURES FOR PRODUCING THEREOF |
| IT24951/81A IT1195289B (en) | 1980-11-10 | 1981-11-10 | DRUG PROVIDED WITH ACTIVITY AGAINST ANXIETY AND ANXIETY LAYERS AND PROCEDURE FOR THE PREPARATION OF SUCH DRUG |
| DE19813144682 DE3144682A1 (en) | 1980-11-10 | 1981-11-10 | Pharmaceutical compositions for anxiety neuroses and neuroses similar thereto, as well as psychosomatic complications, in particular constitutional anxiety neuroses |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8006135A NL8006135A (en) | 1980-11-10 | 1980-11-10 | MEDICINAL PRODUCT WITH ANXIETY AND ANXIETY EQUIVALENTS EFFECTIVE EFFECT AND METHOD FOR PREPARING SUCH A MEDICINE. |
| NL8006135 | 1980-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8006135A true NL8006135A (en) | 1982-06-01 |
Family
ID=19836142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8006135A NL8006135A (en) | 1980-11-10 | 1980-11-10 | MEDICINAL PRODUCT WITH ANXIETY AND ANXIETY EQUIVALENTS EFFECTIVE EFFECT AND METHOD FOR PREPARING SUCH A MEDICINE. |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE890988A (en) |
| DE (1) | DE3144682A1 (en) |
| FR (1) | FR2493703B1 (en) |
| IT (1) | IT1195289B (en) |
| NL (1) | NL8006135A (en) |
| SE (1) | SE8106621L (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (en) * | 1963-07-09 | 1968-01-15 | Ciba Geigy | Process for the production of new amino acids |
| US3947579A (en) * | 1974-06-03 | 1976-03-30 | Nelson Research & Development Company | Method and composition for potentiating neuroleptic drugs |
| GB1547609A (en) * | 1975-04-28 | 1979-06-20 | Nelson Res & Dev | Potentiated hypotensive composition |
| US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
| US4129652A (en) * | 1976-08-16 | 1978-12-12 | Nelson Research & Development Company | Method for potentiating neuroleptic drugs |
| NL7706429A (en) * | 1977-06-10 | 1978-12-12 | Univ Erasmus | PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT HAVING AN ANXIETY AND ANY RELIGIOUS ACTION AND FORMED MEDICINAL PRODUCT WITH SUCH ACTION. |
-
1980
- 1980-11-10 NL NL8006135A patent/NL8006135A/en not_active Application Discontinuation
-
1981
- 1981-11-04 BE BE0/206439A patent/BE890988A/en not_active IP Right Cessation
- 1981-11-09 SE SE8106621A patent/SE8106621L/en not_active Application Discontinuation
- 1981-11-09 FR FR8120935A patent/FR2493703B1/en not_active Expired
- 1981-11-10 DE DE19813144682 patent/DE3144682A1/en not_active Withdrawn
- 1981-11-10 IT IT24951/81A patent/IT1195289B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2493703B1 (en) | 1986-06-27 |
| DE3144682A1 (en) | 1982-06-24 |
| IT1195289B (en) | 1988-10-12 |
| FR2493703A1 (en) | 1982-05-14 |
| IT8124951A0 (en) | 1981-11-10 |
| SE8106621L (en) | 1982-05-11 |
| BE890988A (en) | 1982-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9220290B2 (en) | Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same | |
| JP3930808B2 (en) | Yeast-derived functional peptide having anti-stress function, anti-fatigue function, premenstrual syndrome and menstrual pain alleviating function and function as neurotrophic factor and method for producing the same | |
| CN100464782C (en) | Remedy for fibromyalgia | |
| US6689399B1 (en) | Transdermal delivery of an anti-inflammatory composition | |
| RU2095060C1 (en) | Composition showing analgetic or antiinflammatory activity, a method of analgia or treatment of allergic diseases | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| EP0906111B1 (en) | Composition and method for treating herpes simplex | |
| CN114767729A (en) | Application of medicinal composition of Qudesheng snake or preparation thereof in preparation of medicines for preventing, relieving, and assisting in treating or treating facial spasm or endogenous wind | |
| DE2250032A1 (en) | MEDICINAL PRODUCTS BASED ON LYSINE DERIVATIVES FOR COMBATING LEUCOPENIA AND ANOMALIES OF WHITE BLOOD CELLS OF DIFFERENT AETIOLOGY | |
| EP0615750A2 (en) | Treatment of a group of related disorders | |
| NL8006135A (en) | MEDICINAL PRODUCT WITH ANXIETY AND ANXIETY EQUIVALENTS EFFECTIVE EFFECT AND METHOD FOR PREPARING SUCH A MEDICINE. | |
| Hao et al. | A comparative clinical study of the effect of WeiniCom, a Chinese herbal compound, on alleviation of withdrawal symptoms and craving for heroin in detoxification treatment | |
| WO1995008318A2 (en) | Medicinal substance with anti-infection properties and for use in the treatment of infertility and protection of pregnancy | |
| CN1434710A (en) | Specific therapeutic composition for treating AIDS | |
| JPS59116219A (en) | Novel medicine mixture containing combination of central analgesic and vitamin b 12 or derivative as active component | |
| EP0402208A1 (en) | Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect | |
| Henauer et al. | Multi-centre double-blind comparison of terfenadine once daily versus twice daily in patients with hay fever | |
| RU2071342C1 (en) | Method of treatment of cirrhotic form of lung tuberculosis | |
| DE102004063363A1 (en) | Composition for treatment and prevention of bronchial disease or allergy and for strengthening immune system, contains capsaicin or its derivatives | |
| Grechko et al. | Use of transcutaneous electrical nerve stimulation in the complex treatment of glossalgia | |
| Joshi et al. | Vitamins B1, B6, and B12 in the adjunctive treatment of schizophrenia: Further studies to examine the effect of reduction of chlorpromazine dosage | |
| MANN | The initiation of treatment of unmanageable psychotics with intramuscular administration of trifluoperazine combined with chlorpromazine | |
| SPIES et al. | Adenylic acid in human nutrition | |
| CN113509513A (en) | Combined injection | |
| Hecker | Efficacy and tolerance of ivy extract (Prospan®) in patients suffering from respiratory tract diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| A85 | Still pending on 85-01-01 | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |